The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Open accessAbstract
Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial. Trial registration number: NCT02330926.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationAmerican College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., GALVÃO, D. A., Pinto, B. M., IRWIN, M. L., WOLIN, K. Y., SEGAL, R. J., LUCIA, A., et al. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e0c112 · Cited by 2,781
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Self-citationSpeck, R. M., Courneya, K. S., Mâsse, L. C., Duval, S., & Schmitz, K. H. (2010) · Journal of Cancer Survivorship · doi:10.1007/s11764-009-0110-5 · Cited by 1,352
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Self-citationDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Cited by
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia
Peixoto da Silva, S., Santos, J. M. O., Costa e Silva, M. P., Gil da Costa, R. M., & Medeiros, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12528 · Cited by 371
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions
Wang, T., Zhou, D., & Hong, Z. (2025) · MedComm · doi:10.1002/mco2.70030 · Cited by 46
Metadata
- Authors
- Solheim, T. S., Laird, B. J. A., Balstad, T. R., Bye, A., Stene, G., Baracos, V., Strasser, F., Griffiths, G., Maddocks, M., Fallon, M., Kaasa, S., & Fearon, K.
- Venue
- BMJ Supportive & Palliative Care
- Publisher
- BMJ
- Published
- 2018-02-09
- Volume
- 8
- Issue
- 3
- Pages
- 258-265
- ISSN
- 2045-435X (ISSN-L)
- 2045-4368
- OpenAlex
- W2788888327
- Cited by
- 178
- References
- 6
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. https://app.cochat.ai/papers/10.1136/bmjspcare-2017-001440
- The paper
- Solheim, T. S., Laird, B. J. A., Balstad, T. R., Bye, A., Stene, G., Baracos, V., Strasser, F., Griffiths, G., Maddocks, M., Fallon, M., Kaasa, S., & Fearon, K. (2018). Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Supportive & Palliative Care. https://doi.org/10.1136/bmjspcare-2017-001440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.